Serina Therapeutics is moving SER-252 into the next cohort of its Phase 1b Parkinson’s study after a blinded Cohort 1 review supported continued dose escalation. For investors, the stated milestone is topline data from the single-ascending-dose portion, which the company expects in the first half of 2027.

Key Highlights

  • Serina Therapeutics expects topline results from the single-ascending-dose portion in the first half of 2027.
  • Lowest-dose observations included sustained apomorphine exposure and periods of motor-function improvement in individual patients.
  • The SER-252-1b study is randomized, double-blind and placebo-controlled, with safety, tolerability and pharmacokinetic measures.

Serina Therapeutics, Inc. (AMEX: SER) is advancing SER-252 into the next cohort of its ongoing Phase 1b study in patients with advanced Parkinson’s disease.

Blinded Cohort 1 Review Supports Dose Escalation

An independent Safety Monitoring Committee completed its blinded review of Cohort 1 and recommended that the study proceed to the next dose level. Safety and tolerability observations also supported continued advancement. The randomized, double-blind, placebo-controlled study is evaluating subcutaneous SER-252 for safety, tolerability and pharmacokinetics.

SER-252 Moves Toward Further Clinical Data

Dose escalation is overseen by the independent Safety Monitoring Committee. SER-252 is designed as a long-acting formulation of apomorphine delivered by subcutaneous injection.